Hansa Biopharma: Improved use of IDEFIRIX - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Hansa Biopharma: Improved use of IDEFIRIX - Redeye

{newsItem.title}

Hansa delivers a healthy increase in patients using IDEFIRIX. Discounts and rebates offset this, and the net sales align with expectations. We welcome ongoing adjustments for discounts and rebates, which reduces the need for annual larger “true-ups”. The impact on the valuation and the outlook is likely related to the outlook for discounts and rebates, which could stabilise at a lower level going forward. In Q3, the total level of these provisions was approximately 43%. When adjusting for provisions actually relating to Q3, net sales would have been a very impressive SEK 64.6m and rebates of 7%

Länk till analysen i sin helhet: https://www.redeye.se/research/1043867/hansa-biopharma-improved-use-of-idefirix?utm_source=finwire&utm_medium=RSS

Nyheter om Hansa Biopharma

Läses av andra just nu

Om aktien Hansa Biopharma

Senaste nytt